Search

Your search keyword '"Hanna K Sanoff"' showing total 127 results

Search Constraints

Start Over You searched for: Author "Hanna K Sanoff" Remove constraint Author: "Hanna K Sanoff" Search Limiters Full Text Remove constraint Search Limiters: Full Text
127 results on '"Hanna K Sanoff"'

Search Results

1. Qualitative evaluation of barriers and facilitators to hepatocellular carcinoma care in North Carolina.

2. Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.

3. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk.

4. INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis.

5. Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

6. Supplementary Table 8 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

7. Supplementary Table 12 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

8. Supplementary Table 7 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

9. Supplementary Methods from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

10. Supplementary Table 5 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

11. Supplementary Table 9 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

12. Supplementary Table 6 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

13. Data from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

14. Supplementary Table 4 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

15. Supplementary Table 3 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018

17. Data from Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib

18. Figure S1, Table S1, Table S2, Table S3, Table S4, Table S5, Table S6 from Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib

19. Predictive Modeling for Adverse Events and Risk Stratification Programs for People Receiving Cancer Treatment

20. Trimodality Therapy vs Definitive Chemoradiation in Older Adults With Locally Advanced Esophageal Cancer

21. Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer

22. Medicare/Medicaid Insurance, Rurality, and Black Race Associated With Provision of Hepatocellular Carcinoma Treatment and Survival

23. Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib

24. Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date

25. Patient-Oncologist Communication Regarding Oral Chemotherapy During Routine Office Visits

26. A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer

27. Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer

28. Association between Concomitant Use of Hydrochlorothiazide and Adverse Chemotherapy-Related Events among Older Women with Breast Cancer Treated with Cyclophosphamide

29. KDR genetic predictor of toxicities induced by sorafenib and regorafenib

30. Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer

31. Molecular and Clinical Characterization of a Claudin-Low Subtype of Gastric Cancer

32. A phase I evaluation of the effect of curcumin on dose-limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors

33. Improving Treatment Approaches for Rectal Cancer

34. Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer

35. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

36. Geriatric Assessment Predicts Hospitalization Frequency and Long-Term Care Use in Older Adult Cancer Survivors

37. Cancer of unknown primary

38. All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide

39. Stereotactic Body Radiation Therapy for Recurrent, Isolated Hepatocellular Carcinoma Lymph Node Metastasis With or Without Prior Liver Transplantation

40. DISPARITIES AND HEALTH EQUITY: Racial Differences in Patterns of Health Care Access in a Cohort of Cancer Survivors: A Latent Profile Analysis Approach

41. Managing Grief, Loss, and Connection in Oncology-What COVID-19 Has Taken

42. Telemedicine for Cancer Care in the Time of COVID-19

43. Multicenter, randomized, double‐blind phase 2 trial of <scp>FOLFIRI</scp> with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer

44. Frailty and skeletal muscle in older adults with cancer

45. 1701P Impact of the CARG score and treatment intensity on survival and toxicity outcomes in older adults with non-colorectal gastrointestinal (GI) cancers

46. Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions

47. Hospice Utilization and Its Effect on Acute Care Needs at the End of Life in Medicare Beneficiaries With Hepatocellular Carcinoma

48. Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice

49. Comparison of Medicare claims-based proxy measures of poor function and associations with treatment receipt and mortality in older colon cancer patients

50. Evaluating Surveillance Patterns after Chemoradiation-Only Compared with Conventional Management for Older Patients with Rectal Cancer

Catalog

Books, media, physical & digital resources